Ahsen Mehmet Eren, Boren Todd P, Singh Nitin K, Misganaw Burook, Mutch David G, Moore Kathleen N, Backes Floor J, McCourt Carolyn K, Lea Jayanthi S, Miller David S, White Michael A, Vidyasagar Mathukumalli
IBM Research, Yorktown Heights, NY, USA.
The University of Tennessee, College of Medicine, KnoxvilleTN, USA.
BMC Genomics. 2017 Mar 27;18(Suppl 3):233. doi: 10.1186/s12864-017-3604-y.
Metastasis via pelvic and/or para-aortic lymph nodes is a major risk factor for endometrial cancer. Lymph-node resection ameliorates risk but is associated with significant co-morbidities. Incidence in patients with stage I disease is 4-22% but no mechanism exists to accurately predict it. Therefore, national guidelines for primary staging surgery include pelvic and para-aortic lymph node dissection for all patients whose tumor exceeds 2cm in diameter. We sought to identify a robust molecular signature that can accurately classify risk of lymph node metastasis in endometrial cancer patients. 86 tumors matched for age and race, and evenly distributed between lymph node-positive and lymph node-negative cases, were selected as a training cohort. Genomic micro-RNA expression was profiled for each sample to serve as the predictive feature matrix. An independent set of 28 tumor samples was collected and similarly characterized to serve as a test cohort.
A feature selection algorithm was designed for applications where the number of samples is far smaller than the number of measured features per sample. A predictive miRNA expression signature was developed using this algorithm, which was then used to predict the metastatic status of the independent test cohort. A weighted classifier, using 18 micro-RNAs, achieved 100% accuracy on the training cohort. When applied to the testing cohort, the classifier correctly predicted 90% of node-positive cases, and 80% of node-negative cases (FDR = 6.25%).
Results indicate that the evaluation of the quantitative sparse-feature classifier proposed here in clinical trials may lead to significant improvement in the prediction of lymphatic metastases in endometrial cancer patients.
通过盆腔和/或腹主动脉旁淋巴结转移是子宫内膜癌的主要危险因素。淋巴结切除术可降低风险,但会伴有显著的合并症。I期疾病患者的发生率为4 - 22%,但尚无准确预测其发生的机制。因此,原发性分期手术的国家指南包括对所有肿瘤直径超过2cm的患者进行盆腔和腹主动脉旁淋巴结清扫。我们试图确定一种强大的分子特征,能够准确分类子宫内膜癌患者淋巴结转移的风险。选择86例年龄和种族匹配、在淋巴结阳性和阴性病例中均匀分布的肿瘤作为训练队列。对每个样本进行基因组微小RNA表达谱分析,作为预测特征矩阵。收集了一组独立的28个肿瘤样本,并进行类似的特征分析,作为测试队列。
设计了一种特征选择算法,用于样本数量远小于每个样本测量特征数量的应用。使用该算法开发了一种预测性微小RNA表达特征,然后用于预测独立测试队列的转移状态。使用18种微小RNA的加权分类器在训练队列中准确率达到100%。应用于测试队列时,该分类器正确预测了90%的淋巴结阳性病例和80%的淋巴结阴性病例(错误发现率 = 6.25%)。
结果表明,在此临床试验中对所提出的定量稀疏特征分类器进行评估,可能会显著改善子宫内膜癌患者淋巴转移的预测。